Status: Recruiting
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
The purpose of this study is to find out whether the combination of botensilimab and balstilimab (BOT/BAL) is a safe and effective treatment that causes few or mild side effects for people with mismatch repair proficient (MMRp)/microsatellite stable (MSS) locally advanced rectal adenocarcinoma. The investigators will also find out whether BOT/BAL is an effective treatment when given in combination with standard chemotherapy.
Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Jun 16, 2026Locations: 7
Eligibility criteria
Willing and able to provide written informed consent for trial. [+12]
Recurrent rectal cancer. [+15]